PTK2 and breast cancer: Of note, combination therapies targeting FAK alongside the alternative T-cell costimulatory receptors namely tumor necrosis factor receptor superfamily, member 4 (OX-40) and tumor necrosis factor receptor superfamily member 9 (4-1BB), triggered immune responses involved in the regression of murine mammary tumors [198].